Connect with us

Technology

NanoHive Medical and Canary Medical Announce Strategic Partnership to Develop and Commercialize Smart Spinal Cages

Published

on

Collaboration brings together Canary’s proven active implant technology and NanoHive’s advanced spinal implant design to unlock next-generation data-driven spinal care Global spinal fusion market estimated at ~$6-9 billion today and projected to grow to ~$1316 billion over the next decade

VANCOUVER, BC and WOBURN, Mass., April 20, 2026 /PRNewswire/ — Canary Medical, a medical technology company pioneering active implantable platforms and AI-driven analytics, and NanoHive Medical, a leading innovative 3D printed spinal implant technology company, today announced an exclusive partnership to jointly develop next-generation smart spinal cages that integrate Canary Medical’s proprietary implantable sensing technology with NanoHive’s proprietary Hive™ Soft Titanium® spinal implant design capabilities.

The partnership unites two organizations focused on advancing spine care through intelligent implant technology. By integrating smart sensing capabilities into spinal interbody fusion cages, the companies aim to deliver objective, actionable data that enhances visibility into patient recovery, biomechanics, and fusion progression. This approach is designed to support more informed clinical decision-making and strengthen outcomes across the continuum of care.

Spinal fusion outcomes remain variable, with published data suggesting that nearly 50 percent of patients report some degree of dissatisfaction following their procedure, driven by persistent pain, functional limitations, and uncertainty around fusion progression. Today, recovery is assessed primarily through periodic imaging and patient-reported symptoms, offering only episodic snapshots rather than continuous insight. Smart spinal cages offer a new paradigm by embedding sensing technology directly into the implant to generate objective, longitudinal data on fusion progression, segment mobility, and patient activity, thereby enabling earlier identification of recovery deviations, more personalized rehabilitation, and data-informed intervention. Building on Canary Medical’s proven FDA-cleared smart knee platform, the partnership with NanoHive extends validated active implant architecture into spine to address a  large market with significant unmet need.     

The global spinal fusion market, driven primarily by lumbar procedures, is estimated at $6–$9 billion today and projected to exceed $13–$16 billion over the next decade, supported by an aging population and rising rates of degenerative spine disease. With more than one million procedures performed globally each year, the companies believe data-enabled spinal cages can establish a differentiated, premium segment within a large and established implant market, aligning with the healthcare system’s increasing emphasis on measurable outcomes and valuebased care.

“Canary Medical was founded on the belief that medical devices should do more than provide structural support, they should be interconnected and collect real-time data from the patient,” said Dr. Bill Hunter, Founding Member, CEO & CMO of Canary Medical. “NanoHive has developed an impressive portfolio of innovative spinal implants that are a perfect fit for our technology, with the design allowing space for our smart implant while maintaining the porous structure and ideal modulus that promotes bone growth and stability. By combining our proven smart implant platform with NanoHive’s design expertise, we have a unique opportunity to redefine what spinal implants can deliver for surgeons and patients.”

NanoHive Medical has built its reputation on advanced engineering, porous structures, and implant designs that support bone integration and stability. Through this collaboration, the company will accelerate its smart technology development efforts by integrating Canary Medical’s smart technology into its spinal cage platforms, creating a differentiated category of implants that support both mechanical and clinical performance.

“NanoHive’s mission is to leverage the success of our Soft Titanium platform technology to become a leader in spinal fusion personalization,” said Patrick O’Donnell, President & CEO of NanoHive Medical. “Canary Medical’s leadership in implantable sensing technology makes them the ideal partner as we move into the era of intelligent spine implants. This collaboration is an important milestone in delivering patients, surgeons and other spinal fusion stakeholders a tool that generates meaningful – ultimately predictable – clinical data to guide better outcomes. In addition, the partnership allows us to substantially reduce development and regulatory risks and costs.”  

Joint development efforts will begin immediately, focusing on design integration, engineering validation, and defining key clinical applications. Additional updates regarding development milestones and future clinical plans will be announced as progress continues.

About Canary Medical  
Canary Medical is a medical technology company pioneering active implantable platforms and AI-driven analytics to build a future where connected devices continuously inform treatment and lower the overall cost of healthcare. Its patented canturio®te technology powers the world’s first FDA-approved smart knee that autonomously collects and transmits objective mobility and joint performance data from inside the body. Canary has built one of the largest real-world datasets in total joint arthroplasty, supporting more informed clinical decisions and measurable improvements in patient recovery. The company is leveraging its core sensing, power, and data architecture to expand intelligent implants across additional therapeutic categories.

For more information contact us at admin@canarymedical.com or visit www.canarymedical.com. Follow Canary Medical on LinkedIn.

About NanoHive Medical
NanoHive Medical, LLC is a commercial-stage innovation pioneer in 3D printed spinal interbody fusion implants and instrumentation. The company’s mission is to be the leader in spinal fusion personalization by leveraging its Hive™ Soft Titanium® interbody fusion lattice technology in the $3.2B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences.

NanoHive Medical is located in Woburn, Massachusetts U.S.A.

Website: www.nanohive.com

Canary Medical Investor & Media Contact 
Monica Kendrick
Chief Communications Officer
mkendrick@canarymedical.com 

NanoHive Medical Investor & Media Contact 
Patrick O’Donnell
CEO & President
patrick.odonnell@nanohive.com

Legal Disclaimers
The information contained in this press release, including any accompanying oral commentary, is provided solely for the purpose of acquainting you, as its recipient, with Canary Medical and NanoHive Medical and their subsidiaries (the “Companies”, “we”, “us” or “our”) and their respective executive personnel.  

Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the successful completion of research and development, completion of clinical trials, marketing of the products described above, acceptance of such products by the medical community, regulatory approvals, and numerous other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. The Companies do not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will the Companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. 

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of the Companies, nor will we make any offer, solicitation or sale of such securities in any state, province or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.   

All trademarks are the exclusive property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanohive-medical-and-canary-medical-announce-strategic-partnership-to-develop-and-commercialize-smart-spinal-cages-302746681.html

SOURCE NanoHive Medical

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Tradr to Ring Opening Bell at Cboe to Celebrate SpaceX ETF Launches

Published

on

By

Tradr ETFs will ring Cboe’s Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and short exposure to the newly public SpaceX stock.

Firm to commemorate the launch of SPCM and SPCG from the center of the world’s largest options trading floor

NEW YORK, June 14, 2026 /PRNewswire/ — Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that its team will ring the Opening Bell at Cboe Global Markets at 8:30 am on Monday, June 15, 2026. The ceremony, to be broadcast live on CNBC, will commemorate the expected start of trading for the Tradr 2X Long SpaceX Daily ETF (Cboe: SPCM) and the Tradr 2X Short SpaceX Daily ETF (Cboe: SPCG).

We’re excited to bring both bullish and bearish leveraged exposure to one of the market’s most closely watched stocks

SPCM and SPCG seek to provide traders with 200% leveraged bullish and bearish exposure to SpaceX (Nasdaq: SPCX), one of the most anticipated public offerings in market history.

“Few companies have captured the imagination of investors quite like SpaceX, and we’re proud to mark the launch of SPCM and SPCG by ringing the Opening Bell at Cboe,” said Russell Tencer, President of Tradr ETFs. “Cboe has been an outstanding partner to Tradr since our inception, and there is no better place to celebrate products built for traders by traders. We’re excited to bring both bullish and bearish leveraged exposure to one of the market’s most closely watched stocks and to do so from the center of the options trading world.”

Monday’s expected launch expands Tradr’s growing lineup of leveraged ETFs focused on the rapidly evolving space economy. The firm also offers the Tradr 2X Long ASTS Daily ETF (Cboe: ASTX) and the Tradr 2X Long FLY Daily ETF (Cboe: FLYT), providing 200% leveraged long exposure to two other closely watched companies helping shape the future of space-based communications and aerospace innovation.

Tradr’s lineup of 65 leveraged ETFs represents over $7 billion in assets under management. Some of its notable tickers on trending stocks include SNXX and SNDQ, which provide long and short exposure to SanDisk (SNDK). Tradr’s strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.

For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit www.tradretfs.com.

About Tradr ETFs
Tradr ETFs are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.

IMPORTANT RISK INFORMATION
Tradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund’s return as much as, or more than, the return of the underlying security.

Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.

Leverage increases the risk of a total loss of an investor’s investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.

The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund’s underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.

ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.

ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting www.tradretfs.com. The Prospectus should be read carefully before investing.

Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000965

View original content to download multimedia:https://www.prnewswire.com/news-releases/tradr-to-ring-opening-bell-at-cboe-to-celebrate-spacex-etf-launches-302799509.html

SOURCE Tradr ETFs

Continue Reading

Technology

Changan Group Unveils Its In-house Developed ADAS — SDA Pilot

Published

on

By

CHONGQING, China, June 14, 2026 /PRNewswire/ — At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO, CHANGAN DEEPAL and AVATR at Hall N8, and officially launched its self-developed Advanced Driver-Assistance System, SDA Pilot.

At the press conference, Zhu Huarong, Chairman of Changan Group, stated: “Changan will work together with partners and users worldwide to make ADAS better, more practical, and more accessible, protecting every journey with smart technology.” It is announced that the CHANGAN NEVO Q06 will come standard with SDA Pilot across all trim levels and hit its domestic market in the second half of 2026.

SDA Pilot Takes the Spotlight: Three-tier Safety Defenses Upgrade the ADAS Experience

As Changan’s latest technological achievement in smart mobility, SDA Pilot breaks the boundaries of traditional physical safety and establishes three comprehensive safety defense systems covering physical well-being, mental comfort and emotional interaction.

The entry-level SDA Pilot Pro comes standard with LiDAR, capable of identifying obstacles in low-light conditions such as at night or in tunnels two seconds faster than the human eye. Supported by the globally leading SDA Central Ring Network Architecture, the system cuts response time by an additional 150 milliseconds. SDA Pilot Max, leverages over 20 million high-quality real-world driving data segments for training, delivering exceptional perception and predictive capabilities to confidently navigate complex, high-frequency commuting scenarios. The top-tier SDA Pilot Ultra is integrated with the VLM (Vision Language Model), which greatly enhances the vehicle’s environmental perception and enables interactive advanced driver-assistance functions, turning the vehicle into an intuitive travel companion. In the future, an active driver incapacitation protection function will also be introduced to safeguard driving safety at the first moment.

While continuously evolving its ADAS user experience, Changan remains committed to its safety bottom line, clearly reminding: “Driver assistance is not autonomous driving. Drivers are still required to take on the core responsibilities of real-time monitoring and taking over control at any time.”

Advancing the “1445” Global Strategy: 17 Years of Intelligent R&D Build Solid Safety Foundations

Changan Group lives by the tenet of “Intelligence defines Changan.” As a core component of the “1445” Global Strategy that underpins four transformation priorities (The four priorities refer to: intelligent mobility, electrification, a unified ecosystem, and globalization), intelligent mobility stands as the primary driving force for Changan’s upgrading. The company is committed to building a world-class auto group with global competitiveness and independent core technologies, aiming to rank among the world’s top 10 automobile brands by 2030. The launch of SDA Pilot marks a landmark achievement of this strategy in the advanced driving-assistance sector.

Behind this technological breakthrough lies a solid intelligent foundation built by Changan over 17 years. Since establishing its intelligent R&D team in 2009, Changan has forged ahead in uncharted technological territories and built the China’s only national key laboratory dedicated to intelligent vehicle safety technology — CHANGAN SDA LAB. The lab supports round-the-clock global collaborative testing with more than 400,000 virtual simulation scenarios.

Over the past five years, more than 2,000 Changan engineers have completed over 5 million kilometers of real-road tests across Chongqing’s notoriously complex road conditions, covering 185 typical driving scenarios. Rich field experience has been embedded into the system, which keeps evolving based on user feedback and forms the unshakable safety strength of SDA Pilot.

Empowered by intelligent technologies, Changan continues to accelerate its global footprint. To date, the group has established 22 overseas manufacturing bases with an annual capacity of 350,000 vehicles, and 1,124 overseas sales outlets, covering 118 countries and regions, with 41 global models launched. In 2025, Changan’s overseas sales reached 637,000 vehicles, a year-on-year increase of 18.9%.

Since the start of 2026, Changan has made successive moves in its globalization strategy: launching the Vast Ocean Plan 2.0 during the AutoChina 2026 in Beijing, establishing four core principles: long-term development, localization, systematization, and responsible ESG practices; and more recently, partnering with the Portuguese Football Federation (FPF) to become the Official Global Partner of the Portugal National Football Team, using sports as a bond to deepen global user connections and brand engagement.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/changan-group-unveils-its-in-house-developed-adas–sda-pilot-302799729.html

SOURCE Changan Group

Continue Reading

Technology

Kakunin Announces Cryptographic Compliance Shield for Google Gemini and OpenAI Agent Ecosystems

Published

on

By

SaaS Compliance Leader Launches First-Class SDK Integrations for Google Antigravity, OpenAI Swarm, and OpenAI Assistants API to Meet Strict MiCA and EU AI Act Standards.

LONDON, June 13, 2026 /PRNewswire-PRWeb/ — Kakunin, the leading compliance infrastructure platform for autonomous AI agents, today announced the release of first-class SDK integrations for Google Antigravity SDK, OpenAI Swarm, and the OpenAI Assistants API.

Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin.

As organizations move autonomous AI agents from sandboxes to production, securing the tools they run has become a critical operational hurdle. The new integrations allow developers to cryptographically secure and audit agent actions in real time, meeting the strict requirements of upcoming regulations like the EU AI Act and MiCA.

Preventing Agent Drift at the Tool Layer

Instead of relying on prompt engineering or system instructions—which are susceptible to jailbreaks—Kakunin secures agent tool execution at the cryptographic layer:

Pre-Flight Scope Verification: Validates that an agent possesses the required permission scope (e.g., trade.execute, file.write) before executing local code.Active-Agent Enforcement: Dynamically halts execution if the agent’s underlying X.509 certificate has been revoked or suspended.Tamper-Evident Auditing: Automatically logs session starts, prompts, responses, tool successes, and error anomalies.

Ecosystem Compatibility out of the Box

The new releases bring seamless, code-first integrations to the industry’s leading agent frameworks:

Google Antigravity SDK: Hook-based runtime protection that automatically secures Gemini-powered tool workflows.OpenAI Swarm: A lightweight class wrapper (KakuninSwarm) that dynamically gates multi-agent handoffs and task executions.OpenAI Assistants API: A polling-loop helper (handle_assistants_requires_action) that streamlines safety checks and tool output formatting in a single call.

Beyond these core OpenAI and Google environments, the new releases also extend Kakunin’s cryptographic shield to the broader agent development community. Out-of-the-box templates and shims are now available for LangChain (KakuninToolGuard), LlamaIndex (KakuninFunctionToolGuard), CrewAI (KakuninCrewAgent), and AutoGen (KakuninConversableAgent), alongside native middlewares for Next.js API routes and raw client libraries for Go, TypeScript, and Python.

“Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin. “By bringing cryptographic X.509 validation directly to Google’s and OpenAI’s agent loops, we are giving developers the peace of mind to deploy agents in highly regulated environments like fintech and healthcare.”

Availability

The new SDK integrations are available immediately:

Python Package: Available on PyPI via pip install kakunin.Playground Notebooks: Developers can test the integrations in 1-click via the official OpenAI Cookbook and Google Gemini Cookbook.Reference Samples: Available on the public Kakunin Samples Repository.

To learn more about securing your autonomous agent workflows, visit kakunin.ai/docs. or visit Conversational GTM for more enquiries.

Media Contact
Palash Bagchi, Immortal Reality PA LLC, 1 4125437290, ai@kakunin.ai, https://www.kakunin.ai/

View original content to download multimedia:https://www.prweb.com/releases/kakunin-announces-cryptographic-compliance-shield-for-google-gemini-and-openai-agent-ecosystems-302798798.html

SOURCE Kakunin

Continue Reading

Trending